BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults

Alina Seidel, Michelle Zanoni, Rüdiger Groß, Daniela Krnavek, Sümeyye Erdemci-Evin, Pascal von Maltitz, Dan Albers, Carina Conzelmann, Sichen Liu, Tatjana Weil, Benjamin Mayer, Markus Hoffmann, Stefan Pöhlmann, Alexandra Beil, Joris Kroschel, Frank Kirchhoff, Jan Münch, Janis A. MüllerFrontiers in Immunology 2022 · DOI

TL;DR

This study demonstrates that a BNT162b2 (Pfizer-BioNTech) booster shot significantly restores and broadens immune protection in young adults who previously received a heterologous "mix-and-match" (AstraZeneca/Pfizer) primary vaccine series. Most notably, the booster elicited neutralizing antibody levels against the Omicron BA.1 variant that were nearly as potent as those against the original SARS-CoV-2 strain, suggesting high-quality immune maturation over time.

What Problem Does This Paper Address?

By late 2021, the emergence of the highly mutated Omicron variant (BA.1) posed a significant challenge to global vaccination efforts due to its ability to evade antibodies. While many individuals in Europe received a heterologous primary series—specifically a ChAdOx1 (AstraZeneca) prime followed by a BNT162b2 (Pfizer) boost—the long-term durability of this specific regimen and its responsiveness to a third "booster" dose against Omicron remained unclear.

The authors sought to determine how humoral (antibody) and cellular (T cell) immunity wanes over seven months in this cohort and whether a third dose could overcome Omicron’s immune-evasive properties.

Methods

The researchers conducted a longitudinal study following a cohort of 23 young, healthy hospital employees (median age 29.5). Key techniques included:

  • Serology: Measuring anti-spike IgG and IgM titers using commercial electrochemiluminescence immunoassays.
  • Pseudovirus Neutralization Assays: Using a vesicular stomatitis virus (VSV) platform to test how well participant sera could neutralize the original B.1 strain, the Delta variant, and the Omicron BA.1 variant.
  • T Cell Analysis: Using Intracellular Cytokine Staining (ICS) and flow cytometry to quantify the production of IFN$\gamma$, IL-2, and TNF$\alpha$ in memory T cells after stimulation with variant-specific spike peptide pools.
  • Statistical Modeling: Employing mixed linear regression models to account for repeated measures and missing data points over the 7-month follow-up.

Datasets

The study utilized a primary longitudinal dataset from a cohort of 23 young adults.

  • Booster Subgroup: 18 participants received the BNT162b2 booster.
  • Cellular Subgroup: 12 participants provided peripheral blood mononuclear cells (PBMCs) for detailed T cell analysis.
  • Benchmarks: Results were compared against the ancestral Wuhan-Hu-1 (B.1) strain and the Delta (B.1.617.2) variant of concern.

Key Insights and Ideas

  • The "Neutralization Gap" Closes: Typically, Omicron shows a massive (often 20-40 fold) drop in neutralization compared to the original strain. However, in this heterologously primed cohort, the booster narrowed this gap significantly. Post-booster neutralization of BA.1 was nearly as effective as neutralization of the ancestral B.1 strain.
  • T Cell Resilience: While antibody levels plummeted over six months (with 55% of participants losing detectable neutralization against Omicron), memory T cells remained cross-reactive. These cells could still recognize spike epitopes from Delta and Omicron even before the booster, likely providing a "backstop" against severe disease.
  • The Benefit of Long Intervals: The authors suggest that the relatively long interval between the first and second doses (8 weeks) and the subsequent 6.5-month gap before the booster may have facilitated superior affinity maturation. This process "trains" B cells to produce higher-quality antibodies that can recognize a broader range of viral mutations.

Key Results

  • Antibody Waning: Total anti-spike antibody titers dropped 8-fold over the 5.5 months following the primary series.
  • Booster Surge: The third dose triggered a 21-fold increase in antibody titers (reaching a median of 25,775 BAU/ml), which was 2-fold higher than the peak reached after the initial primary series.
  • Potent Omicron Response: Neutralization titers against Omicron BA.1 increased by over 88-fold following the booster.
  • Cellular Boost: The booster significantly increased the frequency of spike-specific CD4+ and CD8+ T cells across all tested variants, including Omicron.

Limitations and Future Work

  • Cohort Size and Demographics: The study is limited by a small sample size (n=23) of young, healthy individuals. The results may not be generalizable to elderly or immunocompromised populations who often show different waning patterns.
  • Variant Evolution: The study focused on Omicron BA.1. Since its publication, newer subvariants (like BA.5, XBB, and JN.1) have emerged with even greater immune-evasive properties, requiring further study.
  • Mucosal Immunity: The researchers measured systemic immunity (blood) but did not assess mucosal immunity (IgA in the nose/throat), which is critical for preventing initial infection and transmission.
  • Duration of Protection: While the post-booster surge was impressive, the study does not determine how long this restored immunity lasts beyond the initial two-week post-booster window.

Summary updated

Abstract

In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection after initial vaccinations and the now dominant immune-evasive Omicron variants, 'booster' vaccinations are regularly performed to restore immune responses. Many individuals have received a primary heterologous prime-boost vaccination with long intervals between vaccinations, but the resulting long-term immunity and the effects of a subsequent 'booster', particularly against Omicron BA.1, have not been defined. We followed a cohort of 23 young adults, who received a primary heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, over a 7-month period and analysed how they responded to a BNT162b2 'booster'. We show that already after the primary heterologous vaccination, neutralization titers against Omicron BA.1 are recognizable but that humoral and cellular immunity wanes over the course of half a year. Residual responsive memory T cells recognized spike epitopes of the early SARS-CoV-2 B.1 strain as well as the Delta and BA.1 variants of concern (VOCs). However, the remaining antibody titers hardly neutralized these VOCs. The 'booster' vaccination was well tolerated and elicited both high antibody titers and increased memory T cell responses against SARS-CoV-2 including BA.1. Strikingly, in this young heterologously vaccinated cohort the neutralizing activity after the 'booster' was almost as potent against BA.1 as against the early B.1 strain. Our results suggest that a 'booster' after heterologous vaccination results in effective immune maturation and potent protection against the Omicron BA.1 variant in young adults.
BibTeX
@inproceedings{seidel2022bnt,
  author = {Alina Seidel and Michelle Zanoni and Rüdiger Groß and Daniela Krnavek and Sümeyye Erdemci-Evin and Pascal von Maltitz and Dan Albers and Carina Conzelmann and Sichen Liu and Tatjana Weil and Benjamin Mayer and Markus Hoffmann and Stefan Pöhlmann and Alexandra Beil and Joris Kroschel and Frank Kirchhoff and Jan Münch and Janis A. Müller},
  title = {{BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.882918},
}
Figure